pharmaceutical patents

Printer-friendly version
Eliminating patent rights for COVID vaccines will do more harm than good

Pharmaceutical companies heavily rely on patents as their main vehicle to protect intellectual property.

Printer-friendly version
Before breaking for the summer, the House of Commons Standing Committee on Industry, Science, and Technology considered weakening the patent regulations that support Canada’s pharmaceutical market. Now, prompted by public-sector unions, the Competition Bureau will look at whether pharmaceutical patents are anti-competitive. These investigations have only one result: to harm international investors’ confidence in Canada’s will to protect intellectual property. Furthermore, history suggests that if they succeed in weakening patents, drug costs are unlikely to come down.